Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck

NCT02776137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Head-and-neck Cancer
Squamous Cell Carcinoma

Interventions

DRUG: Docetaxel
RADIATION: Intensity-modulated radiotherapy

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University